Starling Oncology (STLNW) Depreciation & Amortization (CF) (2021 - 2026)

Starling Oncology (STLNW) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 1.83% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $6.8 million (down 0.87% YoY), and the FY2025 full-year result was $6.9 million, up 10.45% from the prior year.
• Depreciation & Amortization (CF) rose to $1.8 million in Q2 2026 per STLNW's latest filing, from $1.6 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.8 million in Q2 2026 and bottomed at $987000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) jumped 49.74% in 2023, then retreated 9.42% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.2 million in 2022, then soared by 32.3% to $1.6 million in 2023, then rose by 8.24% to $1.7 million in 2024, then retreated by 4.39% to $1.6 million in 2025, then climbed by 12.62% to $1.8 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.8 million, $1.6 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.